PLUS1
5.65
-2.35 (-29.38%)
-2.35 (-29.38%)
Upgrade to Real-Time
Afterhours (Closed)
Low
4.5017
High
17.99
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galecto Inc | GLTO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -2.35 | -29.38% | 5.65 | 19:59:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.965 | 5.53 | 7.80 | 5.61 | 8.00 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 5.60 | 5.65 | 0.05 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 41,643 | 8,889,381 | $ 6.17 | $ 54,859,482 | 589,473 | 4.5017 - 17.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:36 | formt | 133 | $ 5.65 | USD |
Galecto Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 142.73M | 25.26M | 19.59M | $ - | $ - | -7.86 | -0.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 72.00k | 0.20% |
Galecto News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLTO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.64 | 16.41 | 4.64 | 7.88 | 3,125,635 | 1.01 | 21.77% |
| 1 Month | 5.05 | 16.41 | 4.5017 | 7.52 | 935,186 | 0.60 | 11.88% |
| 3 Months | 7.80 | 16.41 | 4.5017 | 7.36 | 341,911 | -2.15 | -27.56% |
| 6 Months | 14.26 | 16.41 | 4.5017 | 7.66 | 169,840 | -8.61 | -60.38% |
| 1 Year | 15.77 | 17.99 | 4.5017 | 8.21 | 149,157 | -10.12 | -64.17% |
| 3 Years | 15.77 | 17.99 | 4.5017 | 8.21 | 149,157 | -10.12 | -64.17% |
| 5 Years | 15.77 | 17.99 | 4.5017 | 8.21 | 149,157 | -10.12 | -64.17% |
Galecto Description
| Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
